Kura Oncology (NASDAQ:KURA) Rating Reiterated by HC Wainwright

HC Wainwright restated their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a research report sent to investors on Monday, Benzinga reports. They currently have a $32.00 price target on the stock.

A number of other equities research analysts also recently commented on the company. JMP Securities upped their price objective on Kura Oncology from $22.00 to $32.00 and gave the company a market outperform rating in a report on Wednesday, January 31st. StockNews.com downgraded Kura Oncology from a hold rating to a sell rating in a report on Monday, April 15th. Finally, Wedbush reiterated an outperform rating and issued a $37.00 price objective on shares of Kura Oncology in a report on Wednesday, February 28th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Kura Oncology currently has a consensus rating of Moderate Buy and a consensus price target of $28.28.

Kura Oncology Trading Up 1.3 %

KURA stock opened at $19.00 on Monday. The company has a market cap of $1.45 billion, a P/E ratio of -9.13 and a beta of 0.85. Kura Oncology has a twelve month low of $7.41 and a twelve month high of $24.17. The company has a quick ratio of 12.26, a current ratio of 12.26 and a debt-to-equity ratio of 0.02. The business has a fifty day moving average of $20.70 and a 200-day moving average of $15.44.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Tuesday, February 27th. The company reported ($0.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.01. During the same period in the prior year, the company posted ($0.49) EPS. As a group, equities research analysts expect that Kura Oncology will post -2.35 EPS for the current year.

Insider Buying and Selling at Kura Oncology

In other Kura Oncology news, insider Teresa Brophy Bair sold 2,053 shares of the business’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $17.80, for a total value of $36,543.40. Following the completion of the transaction, the insider now directly owns 68,979 shares of the company’s stock, valued at $1,227,826.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, COO Kathleen Ford sold 1,496 shares of the company’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $17.80, for a total transaction of $26,628.80. Following the completion of the transaction, the chief operating officer now directly owns 21,602 shares of the company’s stock, valued at $384,515.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Teresa Brophy Bair sold 2,053 shares of the company’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $17.80, for a total value of $36,543.40. Following the transaction, the insider now directly owns 68,979 shares of the company’s stock, valued at $1,227,826.20. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 5,867 shares of company stock valued at $104,433. Company insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of KURA. Signaturefd LLC boosted its position in shares of Kura Oncology by 40.4% during the fourth quarter. Signaturefd LLC now owns 5,038 shares of the company’s stock worth $72,000 after buying an additional 1,449 shares during the period. Pale Fire Capital SE acquired a new position in shares of Kura Oncology during the third quarter worth about $92,000. E Fund Management Co. Ltd. boosted its position in shares of Kura Oncology by 12.2% during the third quarter. E Fund Management Co. Ltd. now owns 11,929 shares of the company’s stock worth $109,000 after buying an additional 1,301 shares during the period. AXQ Capital LP acquired a new position in shares of Kura Oncology during the third quarter worth about $118,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Kura Oncology by 352.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,590 shares of the company’s stock worth $124,000 after acquiring an additional 6,692 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.